Press Releases

All Releases
View Summary Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License and Collaboration Agreement With Bristol-Myers Squibb
Wednesday, November 11, 2015
PDF 12.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Preliminary FPA008 Phase 1 Data in Rheumatoid Arthritis Patients Presented at the 2015 ACR Annual Meeting
Tuesday, November 10, 2015
PDF 15.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Immuno-Oncology Research Activities Featured in Poster Presentations at SITC 2015
Thursday, November 5, 2015
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Reports Third Quarter 2015 Results and Provides Business Update
Wednesday, November 4, 2015
PDF 26.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 4
Wednesday, October 28, 2015
PDF 6.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
Thursday, October 15, 2015
PDF 12.9 KB Add to Briefcase
View Summary Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Thursday, October 15, 2015
PDF 86.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces The Presentation of Preliminary FPA008 Phase 1 Trial Data in Rheumatoid Arthritis Patients at the 2015 ACR Annual Meeting
Wednesday, October 7, 2015
PDF 16.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable
Friday, September 25, 2015
PDF 13.2 KB Add to Briefcase
View Summary Five Prime Therapeutics' Phase 1a/1b Trial of FPA008 and OPDIVO (nivolumab) Featured as a Trial-in-Progress at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Friday, September 18, 2015
PDF 17.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous Non Small Cell Lung Cancer and Mesothelioma
Wednesday, September 9, 2015
PDF 19.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1a/1b Trial Evaluating the Immunotherapy Combination of FPA008 and OPDIVO (nivolumab) in Six Tumor Types
Tuesday, September 8, 2015
PDF 17.5 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer
Monday, August 24, 2015
PDF 16.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Reports Second Quarter 2015 Results and Provides Business Update
Thursday, August 6, 2015
PDF 26.1 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Second Quarter 2015 Financial Results and Host Conference Call on August 6
Friday, July 31, 2015
PDF 6.4 KB Add to Briefcase
View Summary Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies
Wednesday, July 15, 2015
PDF 10.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis
Monday, July 13, 2015
PDF 15.9 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Jefferies Healthcare Conference
Thursday, May 28, 2015
PDF 13.0 KB Add to Briefcase
View Summary bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy
Tuesday, May 26, 2015
PDF 17.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces First Quarter 2015 Financial Results
Wednesday, May 13, 2015
PDF 17.3 KB Add to Briefcase
Showing 61-80 of 168 Page: 1 2 3 4 5 6 7 8 9  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
28.95
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Friday, May 26, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.